Bloom Science to Present at the Sachs 8th Annual Neuroscience Innovation Forum

SAN DIEGO, Calif., January 10, 2025 – Bloom Science, Inc., a clinical-stage biotech company focused on the development of novel therapies for metabolic and neurological disorders, today announced that its Chief Executive Officer, Christopher Reyes, Ph.D., will participate as a panelist  of experts focused on next-generation modalities in rare neurological diseases.

Dr. Reyes will also deliver a presentation focused on Bloom’s program and clinical data for BL-001 for the potential treatment of Dravet Syndrome and other DEEs (Developmental and Epileptic Encephalopathies) at the Sachs Associates 8th Annual Neuroscience Innovation Forum.  The conference will take place January 12, 2025, in San Francisco, California preceding the 43rd Annual J.P. Morgan Healthcare Conference.

Details of the panel are as follows:

• 8th Annual Neuroscience Innovation Forum
  Details: Dr. Reyes will a panelist for the session: NextGen Modalities for Rare & Orphan Neurological Diseases
  Conference dates: January 12, 2025
  Presentation Timing: 11:00 a.m. PST

Details of the presentations are as follows:

• 8th Annual Neuroscience Innovation Forum
  Details: Dr. Reyes will deliver a presentation and participate in 1-on-1 meetings
  Conference dates: January 11, 2025
  Presentation Timing: 3:45 p.m. PST

About Bloom Science, Inc. 

Bloom Science, Inc. is a clinical-stage biotech company focused on the development of novel first-in-class therapies for the treatment of metabolic and neurological disorders. Bloom’s research and development activities leverage its expertise in gut-brain axis biology, metabolism and the microbiome to develop innovative therapeutics designed to improve patients’ lives. Bloom’s clinical programs include BL-001, a first-in-class, orally delivered, Live Biotherapeutic Product (LBP) designed to replicate the therapeutic effects of the Ketogenic Diet. Bloom’s proprietary discovery platform, IrisRx™ enables a fundamentally different approach to developing medicines by harnessing our expanding insight into the Gut-Brain Axis to design and develop therapeutics that target novel biology with superior safety profiles. Bloom Science is advancing a deep pipeline of programs, focused in obesity, Dravet syndrome and DEEs, Amyotrophic Lateral Sclerosis (ALS), and other neurodegenerative and cognitive disorders.

Bloom Science to Present at the Sachs 1st Annual Biopharma Obesity Innovation Forum

SAN DIEGO, Calif., January 9, 2025 – Bloom Science, Inc., a clinical-stage biotech company focused on the development of novel therapies for metabolic and neurological disorders, today announced that its Chief Executive Officer, Christopher Reyes, Ph.D., will deliver a presentation focused on Bloom’s obesity program and clinical data at the Sachs Associates 1st Annual Biopharma Obesity Innovation Forum. The conference will take place January 11, 2025, in San Francisco, California preceding the 43rd Annual J.P. Morgan Healthcare Conference.

Details of the presentations are as follows:

• 1st Annual Biopharma Obesity Innovation Forum
  Details: Dr. Reyes will deliver a presentation and participate in 1-on-1 meetings
  Conference dates: January 11, 2025
  Presentation Timing: 2:20 p.m. PST

About Bloom Science, Inc. 

Bloom Science, Inc. is a clinical-stage biotech company focused on the development of novel first-in-class therapies for the treatment of metabolic and neurological disorders. Bloom’s research and development activities leverage its expertise in gut-brain axis biology, metabolism and the microbiome to develop innovative therapeutics designed to improve patients’ lives. Bloom’s clinical programs include BL-001, a first-in-class, orally delivered, Live Biotherapeutic Product (LBP) designed to replicate the therapeutic effects of the Ketogenic Diet. Bloom’s proprietary discovery platform, IrisRx™ enables a fundamentally different approach to developing medicines by harnessing our expanding insight into the Gut-Brain Axis to design and develop therapeutics that target novel biology with superior safety profiles. Bloom Science is advancing a deep pipeline of programs, focused in obesity, Dravet syndrome and DEEs, Amyotrophic Lateral Sclerosis (ALS), and other neurodegenerative and cognitive disorders.

Bloom Science Announces Poster Presentations at the 2024 American Epilepsy Society Annual Meeting

SAN DIEGO, Calif., December 5, 2024 – Bloom Science, Inc., a clinical-stage biotech company focused on the development of novel therapies for metabolic and neurological disorders, today announced that preclinical and clinical data from the company’s BL-001 program will be highlighted in three poster presentations at the 2024 American Epilepsy Society Annual Meeting.  BL-001 is a first-in-class, orally delivered, Live Biotherapeutic Product (LBP) designed to replicate the therapeutic effects of the Ketogenic Diet being developed for the potential treatment of Dravet Syndrome and DEEs (Developmental and Epileptic Encephalopathies). The 2024 American Epilespy Society Annual Meeting is being held December 6-10 in Los Angeles, CA

One presentation will summarize results from the company’s Phase 1 clinical trial, a randomized, double-blind, placebo-controlled MAD (multiple ascending dose) study evaluating 28 days of daily treatment with an oral formulation of BL-001 in healthy subjects.  A second presentation will highlight results from the company’s Phase 0 exploratory clinical study in healthy volunteers of BL-001 to assess strain kinetics and tolerability, followed by fecal microbiota transplant from volunteer-to-mice for seizure protection testing. A third presentation will focus on preclinical development data for BL-001 demonstrating anticonvulsive efficacy in multiple mouse models of epilepsy and in vitro modulation of neuronal hyperexcitation, neuroinflammation, and increased integrity of blood brain barrier and gut barrier.

Details of the presentations are as follows:

Poster #2.373:

Title: Safety, Tolerability, and Strain Kinetics of BL-001, an Orally Delivered Live Biotherapeutic Product, in a Phase 1 Study of Healthy Volunteers

Presenting Author: Louis Licamele, PhD, Chief Development Officer, Bloom Science

Date/Time: Sunday, December 8, 2024, 12-2:00 p.m. PST

Location: Exhibit Hall Los Angeles Convention Center

Poster #2.413:

Title: Reverse Translational Validation of Anti-Epileptic Effect of Prototype BL-001 in a Preclinical Seizure Model from a Phase 0 Trial in Healthy Volunteers

Presenting Author: Brent Nowinski, PhD, Scietnist, Bloom Science

Date/Time: Sunday, December 8, 2024, 12-2:00 p.m. PST

Location: Exhibit Hall Los Angeles Convention Center

Poster #2.414:

Title: Selection of Lead Candidate Bacteria for BL-001, a Live Biotherapeutic Product in Development for the Treatment of Neurological Indications

Presenting Author: Lisa Elmén, PhD, Sr Scientist and Andra Ionescu Tucker, PhD, Scientist, Bloom Science

Date/Time: Sunday, December 8, 2024, 12-2:00 p.m. PST

Location: Exhibit Hall Los Angeles Convention Center

About BL-001 and the Ketogenic Diet

BL-001 is a first-in-class, orally delivered, Live Biotherapeutic Product (LBP) being developed by Bloom Science. BL-001 is designed to replicate the therapeutic effects of the ketogenic diet. Preclinical data has demonstrated replication of the ketogenic diet therapeutic effect in epilepsy models and further demonstrated modulation of gamma aminobutyric acid (GABA) and other key bioenergetic pathways to suppress hyperexcitability which is a key driver in seizures.

The ketogenic diet was initially developed in 1921 to mimic fasting as a treatment for epilepsy. The ketogenic diet is a medical diet that is very-low in carbohydrates and high in fat used to treat epilepsy in children but there is accumulating clinical evidence that the diet is effective for weight loss, reversing metabolic dysfunction and treating mental illness. While the ketogenic diet has been shown to work quite well for patients, it can be an incredible challenge to maintain indefinitely.

About Bloom Science, Inc. 

Bloom Science, Inc. is a clinical-stage biotech company focused on the development of novel first-in-class therapies for the treatment of metabolic and neurological disorders. Bloom’s research and development activities leverage its expertise in gut-brain axis biology, metabolism and the microbiome to develop innovative therapeutics designed to improve patients’ lives. Bloom’s clinical programs include BL-001, a first-in-class, orally delivered, Live Biotherapeutic Product (LBP) designed to replicate the therapeutic effects of the Ketogenic Diet. Bloom’s proprietary discovery platform, IrisRx™ enables a fundamentally different approach to developing medicines by harnessing our expanding insight into the Gut-Brain Axis to design and develop therapeutics that target novel biology with superior safety profiles. Bloom Science is advancing a deep pipeline of programs, focused in Obesity, Dravet syndrome and DEEs, Amyotrophic Lateral Sclerosis (ALS), and other neurodegenerative and cognitive disorders.

Bloom Science to Present at Connecting Microbiome Communities Conference

SAN DIEGO, Calif., November 1, 2024 – Bloom Science, Inc., a clinical-stage biotech company focused on the development of novel therapies for metabolic and neurological disorders, today announced that Sr. Scientist Lisa Elmén, Ph.D., will be presenting at the Connecting Microbiome Communities Conference being held November 3-6, 2024 in San Diego, CA.

Details are as follows:

• Connecting Microbiome Communities Conference
  Details: Dr. Elmén will deliver a scientific presentation titled: IrisRx: A Drug Discovery Platform to Develop Microbiota-based Therapeutics Targeting the Gut-Brain Axis
  Conference dates: November 3-6, 2024
  Presentation Timing: 1:15am PST on November 6, 2024

About Bloom Science, Inc. 

Bloom Science, Inc. is a clinical-stage biotech company focused on the development of novel first-in-class therapies for the treatment of metabolic and neurological disorders. Bloom’s research and development activities leverage its expertise in gut-brain axis biology, metabolism and the microbiome to develop innovative therapeutics designed to improve patients’ lives. Bloom’s clinical programs include BL-001, a first-in-class, orally delivered, Live Biotherapeutic Product (LBP) designed to replicate the therapeutic effects of the Ketogenic Diet. Bloom’s proprietary discovery platform, IrisRx™ enables a fundamentally different approach to developing medicines by harnessing our expanding insight into the Gut-Brain Axis to design and develop therapeutics that target novel biology with superior safety profiles. Bloom Science is advancing a deep pipeline of programs, focused in Obesity, Dravet syndrome and DEEs, Amyotrophic Lateral Sclerosis (ALS), and other neurodegenerative and cognitive disorders.

Bloom Science to Present at 24th Annual Biotech in Europe Forum

SAN DIEGO, Calif., September 24, 2024 – Bloom Science, Inc., a clinical-stage biotech company focused on the development of novel therapies for metabolic and neurological disorders, today announced that its Chief Executive Officer, Christopher Reyes, Ph.D., will be presenting at the 24th Annual Biotech in Europe Forum being held September 25-26, 2024 in Basel Switzerland.

Details are as follows:

• 24^rd Annual Biotech in Europe Forum
  Details: Dr. Reyes will deliver a corporate presentation and participate in 1-on-1 meetings
  Conference dates: September 25-26, 2024
  Presentation Timing: 14:05 CEST on September 25, 2024

About Bloom Science, Inc. 

Bloom Science, Inc. is a clinical-stage biotech company focused on the development of novel first-in-class therapies for the treatment of metabolic and neurological disorders. Bloom’s research and development activities leverage its expertise in gut-brain axis biology, metabolism and the microbiome to develop innovative therapeutics designed to improve patients’ lives. Bloom’s clinical programs include BL-001, a first-in-class, orally delivered, Live Biotherapeutic Product (LBP) designed to replicate the therapeutic effects of the Ketogenic Diet. Bloom’s proprietary discovery platform, IrisRx™ enables a fundamentally different approach to developing medicines by harnessing our expanding insight into the Gut-Brain Axis to design and develop therapeutics that target novel biology with superior safety profiles. Bloom Science is advancing a deep pipeline of programs, focused in Obesity, Dravet syndrome and DEEs, Amyotrophic Lateral Sclerosis (ALS), and other neurodegenerative and cognitive disorders.